Related Experiment Video
Updated: Sep 22, 2025
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
Evaluating standards for 'serious' disease for preimplantation genetic testing: a multi-case study on regulatory
Kate Nakasato1, Beverley Anne Yamamoto2, Kazuto Kato3
1Department of Biomedical Ethics and Public Policy, Graduate School of Medicine, Osaka University, Suita, Japan.
Insights
Regulatory frameworks for preimplantation genetic testing (PGT) vary globally, impacting decisions on genetic disease prevention. This study compares how different countries define disease severity for PGT, offering insights for policy development.
Area of Science:
- Genetics
- Bioethics
- Public Health Policy
Background:
- Global regulatory frameworks for preimplantation genetic testing (PGT) are emerging.
- A consensus exists that PGT can prevent the birth of children with serious genetic diseases.
- However, clear standards for defining disease severity in PGT are often lacking.
Purpose of the Study:
- To analyze and compare how disease severity is defined within PGT regulatory frameworks across different countries.
- To understand the medical and social implications of these definitions.
Main Methods:
- A multi-case study analysis of policy documents from the UK, Western Australia, and Japan.
- Documentary analysis focused on medical indications, evaluation methods, and review frameworks for PGT applications.
Main Results:
- Medical indications for PGT are based on the estimated risk of genetic abnormalities with known clinical deficits.
- Evaluation methods include pre-approved lists (UK) and case-by-case reviews (UK, Western Australia, Japan).
- Review frameworks incorporate lists of factors or disease severity definitions, revealing varied interpretations.
Conclusions:
- PGT regulatory frameworks have significant medical and social impacts on stakeholders.
- The approval circumstances and decision-making processes for PGT are as impactful as its permissibility.
- Findings offer valuable insights for countries revising or developing PGT policies and related technologies.
Background:
A number of countries are leading the way in creating regulatory frameworks for preimplantation genetic testing (PGT). Among these countries, a point of consensus is that PGT may be used to avoid the birth of a child with a serious genetic disease. However, standards for evaluating disease severity in this context are not always clear. Considering the numerous medical and social implications of defining a standard for serious disease, our study sought out to better understand how disease severity for PGT is being defined by analyzing and comparing the regulatory landscapes for PGT in various countries.
Methods:
We carried out a multi-case study analysis using policy documents from the UK, Western Australia, and Japan. Documentary analysis was used to analyze and compare these documents in terms of medical indications for PGT, evaluation methods of applications for PGT, and review frameworks used during the evaluation process, which includes the specific medical and social factors that are considered.
Results:
Within our three case studies, medical indications for PGT are based on an estimated risk of the woman giving birth to a child with a genetic abnormality with known clinical deficits. Evaluation methods for approving applications for PGT include reference to a pre-approved list of genetic conditions (the UK) and case-by-case reviews (all case studies). Review frameworks for case-by-case reviews include reference to a list of considered factors (the UK and Western Australia) and a definition statement of disease severity (Japan), which provide insight into interpretations of disease severity in each context.
Conclusions:
The results of this study point to the possible medical and social impacts of PGT regulatory frameworks on multiple stakeholders. Furthermore, it suggests that impacts in this case are not only caused by whether PGT is permitted or not, but also by the circumstances under which it is allowed and how decisions regarding its approval are made. Our results may serve as valuable insights for countries that already have established policy for PGT but are considering revision, countries that are without policy, and for discussions on related genetic and reproductive technologies.
More Related Videos
05:15Author Spotlight: Assessing the Feasibility of Using Amplitude-Integrated EEG During Neonatal Transport
Published on: June 21, 2024
12:40A Modified Murine Heterotopic Heart Transplant Protocol Matching Contemporary Standards of Aseptic Technique, Anesthesia, and Analgesia
Published on: September 28, 2022